Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2022 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter 2022 Financial Results

EXTON, Pa., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
May 17, 2022 08:04 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC

EXTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” “we,” and “our”) (Nasdaq: IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit...
May 05, 2022 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

EXTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
March 31, 2022 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

EXTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
December 14, 2021 16:32 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Tilsotolimod Updates

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its...
November 08, 2021 16:14 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the...
August 09, 2021 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
May 18, 2021 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Corporate Updates

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of...
April 29, 2021 16:10 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
March 18, 2021 16:15 ET | Source: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...